Cite
Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.
MLA
Stocker, Gertraud, et al. “Clinical Consequences of Chemotherapy Dose Reduction in Obese Patients with Stage III Colon Cancer: A Retrospective Analysis from the PETACC 3 Study.” European Journal of Cancer, vol. 99, Aug. 2018, pp. 49–57. EBSCOhost, https://doi.org/10.1016/j.ejca.2018.05.004.
APA
Stocker, G., Hacker, U. T., Fiteni, F., John Mahachie, J., Roth, A. D., Van Cutsem, E., Peeters, M., Lordick, F., & Mauer, M. (2018). Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study. European Journal of Cancer, 99, 49–57. https://doi.org/10.1016/j.ejca.2018.05.004
Chicago
Stocker, Gertraud, Ulrich T. Hacker, Frédéric Fiteni, Jestinah John Mahachie, Arnaud D. Roth, Eric Van Cutsem, Marc Peeters, Florian Lordick, and Murielle Mauer. 2018. “Clinical Consequences of Chemotherapy Dose Reduction in Obese Patients with Stage III Colon Cancer: A Retrospective Analysis from the PETACC 3 Study.” European Journal of Cancer 99 (August): 49–57. doi:10.1016/j.ejca.2018.05.004.